COMSAT Laboratories' on-board baseband switch development

Work performed at COMSAT Laboratories to develop a prototype on-board baseband switch is summarized. The switch design is modular to accommodate different service types, and the architecture features a high-speed optical ring operating at 1 Gbit/s to route input (up-link) channels to output (down-link) channels. The switch is inherently a packet switch, but can process either circuit-switched or packet-switched traffic. If the traffic arrives at the satellite in a circuit-switched mode, the input processor packetizes it and passes it on to the switch. The main advantage of the packet approach lies in its simplified control structure. Details of the switch architecture and design, and the status of its implementation, are presented

Evidence for long-term variability in the ultra high energy photon flux from Cygnus X-3

A time-correlation analysis of atmospheric Cerenkov pulses by a wide-angle photomultiplier system was previously shown to have present in it a nonrandom component which seemed associated with the Right Ascension (RA) range approx. 20+or-04h. A recent examination of multi-muon events recorded by a photon-decay detector shows a similar time-dependent effect, closely matching the previous results, supporting the suggestion that the effect is of cosmic origin. However, even though Cyg. X-3 lies well inside the region of peak intensity, it does not seem possible to ascribe to it the whole effect, for the implied photon flux appears too large to be reconciled to various gamma-ray measurements of Cyg. X-3. The original data were subjected to a phase-histogram analysis and it as found that only 2.5% of overall recorded data are compatible with a phase-dependent emission from Cyg. X-3. Assuming these events to be gamma rays yields a detected flux of (2.6 + or - 0.3) x 10 to the minus 12th power gamma cm -2s-1 above 5 x 10 to the 14th power eV. Comparing this value with more recent ultra high energy (UHE) photon data from the same source, it is suggested that the available data generally favor a long-term reduction in the Cyg. X-3 inferred luminosity ( 10 to the 13th power eV) by a factor of (1.8 + or - 0.3) per year

Narcotic Drug Detection and Identification through Synchronous Fluorescence Technique

Illegal production of potentially hazardous narcotics as well as various psychotropic drugs is being carried out in the neighbouring countries and international market which is causing narco-terrorism a global havoc. Compared with traditional/natural drugs the synthetic drugs are more smuggled nowadays. Because of the vulnerability of the borders to drug trafficking, India has increased surveillance at borders and coasts and thus has tackled the problem to some extent. Authors developing a Narcotic drug sensor (point sensor) for detection and identification of Narcotic drugs based on Laser Induced Fluorescence more specifically Synchronous Fluorescence Spectroscopy in an effort. Some narcotic samples viz. Caffeine, Quinine and Tramadol were considered for the study. The fluorescence spectrum was studied using our own laboratory-based sensor incorporating charge coupled device-based Spectrometer and Laser source (266 nm wavelength) and commercial system from ‘Horiba Scientific’ incorporating Photomultiplier tube and Xe lamp source

Periodic gamma-ray emissions from Geminga at or = 10(12) eV

Analysis of data from an atmospheric Cerenkov telescope indicated the periodic emission of gamma rays of energy 10 to the 12th power eV, at 60.25 second period, from 2CG 195+4. The gamma ray flux at 99% confidence level is estimated to be 9.5 x 10 to 12 photons/sq cm/s

Scaling in the Bombay Stock Exchange Index

In this paper we study BSE Index financial time series for fractal and multifractal behaviour. We show that Bombay stock Exchange (BSE)Index time series is mono-fractal and can be represented by a fractional Brownian motion.Comment: 11 pages,3 figure

Unique Observations of a Geomagnetic SI^+ -- SI^- Pair: Solar Sources and Associated Solar Wind Fluctuations

The paper describes the occurrence of a pair of oppositely directed sudden impulses (SI), in the geomagnetic field ($\Delta$X), at ground stations, called SI${^{+}}$ -- SI${^{-}}$ pairs, that occurred between 1835 UT and 2300 UT on 23 April 1998. The SI${^{+}}$ -- SI${^{-}}$ pair, was closely correlated with corresponding variations in the solar wind density, while solar wind velocity and the southward component of the interplanetary magnetic field (Bz) did not show any correspondence. Further, this event had no source on the visible solar disk. However, a rear-side partial halo coronal mass ejection (CME) and an M1.4 class solar flare behind the west limb, took place on 20 April 1998, the date corresponding to the traceback location of the solar wind flows. This event presents empirical evidence, which to our knowledge, is the best convincing evidence for the association of specific solar events to the observations of an SI${^{+}}$ -- SI${^{-}}$ pair. In addition, it shows that it is possible for a rear side solar flare to propagate a shock towards the earth.Comment: The paper has just been accepted in the Journal of Geophysical Research (Space Physics) on 20 September 2010. It is 17 pages with 4 figure

Opto-mechanical measurement of micro-trap via nonlinear cavity enhanced Raman scattering spectrum

High-gain resonant nonlinear Raman scattering on trapped cold atoms within a high-fineness ring optical cavity is simply explained under a nonlinear opto-mechanical mechanism, and a proposal using it to detect frequency of micro-trap on atom chip is presented. The enhancement of scattering spectrum is due to a coherent Raman conversion between two different cavity modes mediated by collective vibrations of atoms through nonlinear opto-mechanical couplings. The physical conditions of this technique are roughly estimated on Rubidium atoms, and a simple quantum analysis as well as a multi-body semiclassical simulation on this nonlinear Raman process is conducted.Comment: 7 pages, 2 figure

Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis.

BACKGROUND: The post-thrombotic syndrome frequently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical catheter-directed thrombolysis (hereafter pharmacomechanical thrombolysis ) rapidly removes thrombus and is hypothesized to reduce the risk of the post-thrombotic syndrome. METHODS: We randomly assigned 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation alone (control group) or anticoagulation plus pharmacomechanical thrombolysis (catheter-mediated or device-mediated intrathrombus delivery of recombinant tissue plasminogen activator and thrombus aspiration or maceration, with or without stenting). The primary outcome was development of the post-thrombotic syndrome between 6 and 24 months of follow-up. RESULTS: Between 6 and 24 months, there was no significant between-group difference in the percentage of patients with the post-thrombotic syndrome (47% in the pharmacomechanical-thrombolysis group and 48% in the control group; risk ratio, 0.96; 95% confidence interval [CI], 0.82 to 1.11; P=0.56). Pharmacomechanical thrombolysis led to more major bleeding events within 10 days (1.7% vs. 0.3% of patients, P=0.049), but no significant difference in recurrent venous thromboembolism was seen over the 24-month follow-up period (12% in the pharmacomechanical-thrombolysis group and 8% in the control group, P=0.09). Moderate-to-severe post-thrombotic syndrome occurred in 18% of patients in the pharmacomechanical-thrombolysis group versus 24% of those in the control group (risk ratio, 0.73; 95% CI, 0.54 to 0.98; P=0.04). Severity scores for the post-thrombotic syndrome were lower in the pharmacomechanical-thrombolysis group than in the control group at 6, 12, 18, and 24 months of follow-up (P CONCLUSIONS: Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in a lower risk of the post-thrombotic syndrome but did result in a higher risk of major bleeding. (Funded by the National Heart, Lung, and Blood Institute and others; ATTRACT ClinicalTrials.gov number, NCT00790335 .)